| 50.6 -1.34 (-2.58%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 67.26  |
1-year : | 73.65 |
| Resists | First : | 57.58 |
Second : | 63.06 |
| Pivot price | 54.84  |
|||
| Supports | First : | 48.72 |
Second : | 40.54 |
| MAs | MA(5) : | 52.3 |
MA(20) : | 54.59 |
| MA(100) : | 28.94 |
MA(250) : | 18.98 |
|
| MACD | MACD : | 1.4 |
Signal : | 2.7 |
| %K %D | K(14,3) : | 14.9 |
D(3) : | 17.3 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 63.06 | Low : | 7.57 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CELC ] has closed above bottom band by 16.7%. Bollinger Bands are 13.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 52.57 - 52.86 | 52.86 - 53.09 |
| Low: | 49.14 - 49.49 | 49.49 - 49.78 |
| Close: | 50.07 - 50.61 | 50.61 - 51.05 |
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Wed, 24 Sep 2025
Craig-Hallum Remains a Buy on Celcuity (CELC) - The Globe and Mail
Tue, 23 Sep 2025
The Bull Case For Celcuity (CELC) Could Change Following Expanded Credit Facility and Rising Commercial Ambitions - simplywall.st
Tue, 23 Sep 2025
Goldman Sachs Group Inc. Sells 28,686 Shares of Celcuity, Inc. $CELC - MarketBeat
Mon, 22 Sep 2025
Guggenheim Initiates Coverage of Celcuity (CELC) with Buy Recommendation - Nasdaq
Mon, 22 Sep 2025
Celcuity, Inc. (NASDAQ:CELC) Receives $56.50 Average Price Target from Analysts - MarketBeat
Tue, 16 Sep 2025
Celcuity (CELC) Expands US$500 Million Credit Facility For Enhanced Financial Flexibility - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 42 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 12 (%) |
| Held by Institutions | 84 (%) |
| Shares Short | 5,620 (K) |
| Shares Short P.Month | 3,090 (K) |
| EPS | -3.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.13 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.5 % |
| Return on Equity (ttm) | -134.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -120 (M) |
| Levered Free Cash Flow | -74 (M) |
| PE Ratio | -14.59 |
| PEG Ratio | 0 |
| Price to Book value | 44.38 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|